Ind-Swift Laboratories Ltd
INDSWFTLAB
Company Profile
Business description
Ind-Swift Laboratories Ltd is engaged in the business of manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company caters to diverse therapeutic segments namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitor. It operates in a single segment namely, Bulk Drugs and Pharmaceuticals. Geographically, the company caters to both Indian and international markets, of which, maximum revenue is derived from outside India.
Contact
SCO 850, NAC
Shivalik Enclave
Manimajra
ChandigarhPB160101
INDT: +91 1725061850
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
47
Stocks News & Analysis
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
stocks
Insights from reporting season: So far, so good
We’ve upgraded our fair value estimate for 29 companies, or 40% of those that have reported thus far.
stocks
3 cheap ASX stocks owned by top rated funds
Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,570.90 | 30.80 | -0.36% |
CAC 40 | 8,154.51 | 31.93 | 0.39% |
DAX 40 | 22,287.56 | 27.09 | -0.12% |
Dow JONES (US) | 43,493.51 | 683.14 | -1.55% |
FTSE 100 | 8,659.37 | 3.60 | -0.04% |
HKSE | 23,477.92 | 900.94 | 3.99% |
NASDAQ | 19,644.06 | 318.30 | -1.59% |
Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
S&P 500 | 6,036.09 | 81.43 | -1.33% |
S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
SSE Composite Index | 3,379.11 | 28.33 | 0.85% |